The recent nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services is generating excitement among mass tort attorneys. Known for his history as a trial attorney handling significant personal injury and environmental cases, Kennedy is seen by the plaintiffs’ bar as a potential ally in their legal battles against corporate interests. His background makes him an unconventional choice for the Trump administration, which typically does not align with such perspectives.
Mass tort lawyers see Kennedy’s potential tenure at HHS as an opportunity for increased scrutiny on products regulated by agencies under the department, such as the Food and Drug Administration and the Centers for Disease Control and Prevention. This could lead to new regulations that might challenge the defenses of drug manufacturers in mass tort suits. As reported by Bloomberg Law, lawyers cautiously optimistic about these prospects include Steve Nober of Consumer Attorney Marketing Group, who suggests there could be promising opportunities for the plaintiffs’ bar in the coming years.
Kennedy, who has been critical of pharmaceutical practices, particularly vaccine safety, might aim to reform existing regulatory frameworks. Current FDA Commissioner Robert M. Califf notes that, although decisions are generally made by career civil servants, legal provisions allow higher authorities, like the HHS Secretary, to override FDA rulings.
Such oversight power could potentially be utilized by Kennedy to modify drug and medical device regulations, potentially revoking liability shields for pharmaceutical companies. His stance aligns with the belief among certain attorneys that regulatory bodies often prioritize corporate interests. Fellow attorneys like Mike Papantonio view Kennedy’s potential to curtail the influence of major corporations on health regulators as a possible shift from the “revolving door” culture prevalent between FDA officials and the industry it governs.
While some in the plaintiffs’ bar, such as Ashley Keller from Keller Postman, are welcoming, others, like Ross Wallin from Curium Capital, express caution. This is due to the mixed signals that could emerge from Kennedy’s independent political path and Trump’s known affiliations with business interests. Plaintiffs’ attorney Majed Nachawati describes Trump as a “wild card,” whose influence could either facilitate or hinder Kennedy’s impact within the administration.
In summary, while Kennedy’s nomination has generated enthusiasm, the legal community acknowledges the complexities of his potential appointment and the mixed implications it could have under Trump’s presidency. The full article can be accessed on Bloomberg Law.